Marker Therapeutics appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company’s therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.
Chief Financial Officer, Anthony H. Kim, to present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 11, 2019.
Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.
Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.
The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.
President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.
Data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018).
“Over my career, I’ve had the chance to work with many great companies, a number of which have had a major impact within the biotech sector that led to great advances in patient care. However, I believe Marker Therapeutics’ patient data are truly exceptional, generating excellent complete response rates in a meaningful number of patients to date. ,” said Mr. Kim.
President and CEO, Peter L. Hoang, will be participating in several healthcare conferences this month.
“We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.